|
|
| General |
| Study Status |
Completed |
Application Number /
Requirement Number |
P060039 / PAS002 |
| Date Original Protocol Accepted |
06/13/2008
|
| Date Current Protocol Accepted |
11/19/2013
|
| Study Name |
Chronic Performance Study
|
| Device Name |
ATTAIN STARFIX MODEL 4195 LEAD
|
| General Study Protocol Parameters |
| Study Design |
Prospective Cohort Study
|
| Data Source |
New Data Collection
|
| Comparison Group |
Objective Performance Criterion
|
| Analysis Type |
Analytical
|
| Study Population |
Transit. Adolescent B (as adults) : 18-21 yrs,
Adult: >21
|
| Detailed Study Protocol Parameters |
| Study Objectives |
This study is a non-randomized, multi-site, clinical study of implanted commercially available Model 4195 leads. Data will be collected prospectively; however, retrospective study enrollment will be allowed to include leads implanted through the Attain StarFix Model 4195 LV Lead pre-market study. All enrolled subjects have been implanted with a Model 4195 LV Lead. This study is designed to monitor long term performance of the Model 4195 lead and to identify individual failure modes.The objective of the study is to demonstrate that the Model 4195 lead-related complication-free probability is greater than 92.5% at five years post-implant.
|
| Study Population |
The Attain StarFix Model 4195 steroid eluting, transvenous lead with deployable lobe fixation is intended for chronic pacing and sensing of the left ventricle via the cardiac vein, when used in conjunction with a compatible implantable pulse generator or implantable cardiac defibrillator.
|
| Sample Size |
1,016 patients will be enrolled to achieve an evaluable sample size of 600 for 5-year follow-up for an interim analysis. 120 active centers enrolled in this study.
|
| Key Study Endpoints |
The primary objective of the study is to demonstrate that the Model 4195 lead-related complication-free probability is greater than 92.5% at five years post-implant. Primary objective analysis will include all complications related to lead hardware or design failure. The complication free proportion will be estimated based on the chronic (> 30 days post implant) clinical adverse events including: 1) - Failure to capture, 2) Failure to sense / Undersensing, 3) Threshold rise, 4) Oversensing, 5) Abnormal pacing impedance, 6) Lead insulation breach, 7) Lead conductor fracture, 8) Extracardiac stimulation, 9) Cardiac perforation, 10) Lead dislodgement, and 11) Structural Lead Failure,
|
| Follow-up Visits and Length of Follow-up |
The follow-up schedule for this study is based on utilizing routine, scheduled office/clinic visits and unscheduled office/clinic visits prompted by symptoms or complaints. Follow-up office/clinic visits post-enrollment are to occur at a minimum of every 6 months, no longer than 210 days apart.
|
| Interim or Final Data Summary |
| Interim Results |
The sponsor reports four adverse events (two complications, two observations not adjudicated by the cut-off date), six total study exits (including 2 deaths) and no deviations from the study plan. As of the data cut-off date, two deaths have been reported in this study. These deaths have not been reviewed by the Event Adjudication Committee and tabled as additional information was required from the center. Updated information regarding these deaths will be provided in the next report. There is limited information in this report upon which to make conclusions on the safety of this device.
|
| Actual Number of Patients Enrolled |
1322 subjects
|
| Actual Number of Sites Enrolled |
98 sites
|
| Patient Follow-up Rate |
61.27%
|
| Final Safety Findings |
The Attain StarFix Model 4195 Lead related complication free-rate at 60months is 97.3%, and the lower bound of one-sided 95% confidence interval for the complication-free rate is 95.96%. This results are well above the acceptance boundary of 92.5%.
|
| Final Effect Findings |
During this study duration, a total of 147 elevated thresholds were reported with occurrence rate decreasing from 6.97% at impant to 2.10% at 60 months. In addition, a total of 10 out-of-range pacing impedance events were reported with occurrence rate varying from 0% to 0.35% at different time points from implant to 60 months. A total of 56 returned leads (4.22%) were reported during the study period.
|
| Study Strengths & Weaknesses |
Study Strength:
Excellent device safety: high five-year complication free rate 97.3% ( 95%CI: 95.96%, 98.2%)
Excellent device effectiveness: low five-year occurrence rates of elevated thresholds (2.10%) and out-of-range pacing impedance events (0.26%) at 60 months
Study Weakness:
High attrition rates excluding deaths (38.73%) and including deaths (64.99%)
Lower number of subjects (446) who reached 5-year follow-up post implant than the minimum required 598 subjects
|
| Recommendations for Labeling Changes |
Yes
|
